We recently published Part I of a two-part update series answering some of the more common questions international business operators are asking about the merger control regime under China's Anti-Monopoly Law.
We are now pleased to present Part II of this update series, addressing five further questions (additional to the five addressed in Part I), and providing additional compliance tips of general application.
China's Anti-Monopoly Law has now been in force for 19 months. A number of prohibition and conditional approval decisions under the law's merger control provisions have heightened foreign interest in the regime, particularly amongst multinationals whose annual China turnover is sufficiently high to raise the prospect that some of their M&A deals will qualify for mandatory reporting in China. Representatives of these multinationals may be nervous about submitting their transactions for review under a regime that is not noted for its transparency, and keen for insights into the regime's track-record and Mofcom's priorities when it comes to the review process.
In this update (the first in a two-part series) we provide comments in response to five questions international business operators commonly pose about the AML merger control regime. Part II of this update series, to be published shortly, will address five further questions, and both updates also provide compliance tips of general application.
